Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Replimune (Nasdaq: REPL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
A simultaneous webcast will be available in the Investors section of replimune.com, and a replay will be available for 30 days following the conference.
Positive
- None.
Negative
- None.
News Market Reaction – REPL
In the Dec 18 session, REPL gained 0.31%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 07 | Clinical data update | Positive | +4.8% | Updated RP1 plus nivolumab data with ORR and durable responses at SITC 2025. |
| Nov 06 | Earnings and update | Positive | -0.9% | Fiscal Q2 results and FDA acceptance of RP1 BLA resubmission with set PDUFA date. |
| Oct 20 | Regulatory milestone | Positive | +98.8% | FDA acceptance of RP1 BLA resubmission for advanced melanoma with PDUFA date. |
| Sep 18 | Regulatory update | Negative | -39.4% | Type A meeting feedback on CRL, with path under accelerated approval undetermined. |
| Sep 02 | Meeting scheduled | Negative | +9.3% | Scheduling Type A meeting and warning RP1 program viability without accelerated approval. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news flow shows strong price sensitivity to FDA and RP1 regulatory milestones, with mixed reactions to clinical data and earnings updates.
Over the last few months, REPL’s trajectory has been driven by RP1 regulatory milestones and supporting data. On Sep 2, 2025 and Sep 18, 2025, Type A meeting communications and FDA feedback on the CRL highlighted uncertainty for accelerated approval. Sentiment shifted sharply on Oct 20, 2025 when the FDA accepted the BLA resubmission with a PDUFA date of April 10, 2026, followed by confirmation in the 10-Q and fiscal Q2 update. The Nov 7, 2025 SITC data for RP1 plus nivolumab further reinforced durability signals. Today’s J.P. Morgan conference appearance fits into this ongoing communication cadence without adding new clinical or regulatory data.
Key Terms
oncolytic immunotherapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
